From: Intensive therapy and remissions in rheumatoid arthritis: a systematic review
First Author | Study | Year | Design | Groups | RA Duration | Quality Assessments | Months Follow-up | Treatments | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Allocation | Blinding | Bias Analysis | Control | Intensive | |||||||
Atsumi [28] | C-Opera | 2016 | RCT | 2 | Early | Low risk | Low risk | Low risk | 12 | MTX | Certolizumab/MTX |
Bakker [29] | Camera II | 2012 | RCT | 2 | Early | Low risk | Low risk | Low risk | 24 | MTX | Prednisolone/MTX |
Bijlsma [30] | U-Act-Early | 2016 | RCT | 3 | Early | Low risk | Low risk | Low risk | 24 | MTX | Tocilizumab/MTX |
Breedveld [31] | Premier | 2005 | RCT | 3 | Early | Low risk | Low risk | Low risk | 24 | MTX | Adalimumab/MTX |
Burmester [32] | Function | 2015 | RCT | 4 | Early | Unclear | Unclear | Low risk | 12 | MTX | Tocilizumab/MTX |
Capell [33] | Mascot | 2007 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 12 | MTX or SZP | MTZ/SZP |
Cohen [34] | Reflex | 2006 | RCT | 2 | Est’lishd | Low risk | Low risk | Low risk | 6 | MTX | Rituximab/MTX |
Detert [35] | Hit Hard | 2012 | RCT | 2 | Early | Low risk | Low risk | Low risk | 6 | MTX | Adalimumab/MTX |
Dougadas [36] | Act-Ray | 2013 | RCT | 2 | Est’lishd | Low risk | Low risk | Low risk | 6 | Tocilizumab | Tocilizumab/MTX |
Emery [37] | Avert | 2014 | RCT | 3 | Early | Low risk | Low risk | Low risk | 12 | MTX | Abatacept/MTX |
Emery [38] | Comet | 2008 | RCT | 2 | Early | Low risk | Low risk | Low risk | 12 | MTX | Etanercept/MTX |
Emery [39] | Go Before | 2009 | RCT | 4 | Est’lishd | Low risk | Low risk | Low risk | 6 | MTX | Golimumab/MTX |
Emery [40] | Radiate | 2008 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 6 | MTX | Tocilizumab/MTX |
Emery [41] | Serene | 2010 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 12 | MTX | Rituximab/MTX |
Emery [42] | C-Early | 2017 | RCT | 2 | Early | Low risk | Low risk | Low risk | 12 | MTX | Certolizumab/MTX |
Genovese [43] | RA Beacon | 2016 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 6 | DMARD | Baracitinib/DMARDs |
Genovese [44] | Toward | 2008 | RCT | 2 | Est’lishd | Low risk | Low risk | Low risk | 6 | DMARD | Tocilizumab/DMARD |
Goekoop Ruitermann [45] | BeSt | 2005 | RCT | 4 | Early | Low risk | Low risk | Low risk | 12 | DMARDs | Infliximab/DMARDs or Combination DMARDs |
Grigor [46] | Ticora | 2004 | RCT | 2 | Est’lishd | Low risk | Low risk | Low risk | 18 | Usual Care | Combination DMARDs |
Hetland [47] | Cimestra | 2006 | RCT | 2 | Early^{a} | Unclear | Low risk | Low risk | 12 | MTX | MTX/Ciclosporin |
Horslev Petersen [48] | Opera | 2014 | RCT | 2 | Early^{a} | Low risk | Low risk | Low risk | 12 | MTX | Adalimumab/MTX |
Kavanaugh [49] | Optima | 2013 | RCT | 2 | Est’lishd | Low risk | Low risk | Low risk | 6 | MTX | Adalimumab/MTX |
Kivitz [50] | Brevacta | 2014 | RCT | 2 | Est’lishd | Low risk | Low risk | Low risk | 6 | DMARD | Tocilizumab/DMARD |
Klareskog [51] | Tempo | 2004 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 6 | MTX | Etanercept/MTX |
Kremer [52] | – | 2005 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 12 | MTX | Abatacept/MTX |
Kremer [53] | Lithe | 2011 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 24 | MTX | Tocilizumab/MTX |
Kremer [54] | – | 2012 | RCT | 7 | Est’lishd | Low risk | unclear | Low risk | 6 | MTX | Tofacitinib/MTX |
Kremer [55] | – | 2013 | RCT | 4 | Est’lishd | Low risk | Low risk | Low risk | 6 | DMARD | Tofacitinib/DMARD |
Nam [56] | Empire | 2014 | RCT | 2 | Early^{a} | Low risk | Low risk | Low risk | 12 | MTX | Etanercept/MTX |
Nam [57] | Idea | 2014 | RCT | 2 | Early | Low risk | Low risk | Low risk | 18 | MTX | MTX/infliximab |
Schiff [58] | Attest | 2007 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 12 | MTX | Abatacept/MTX or Infliximab/MTX |
Schipper [59] | – | 2012 | Quasi-Exp | 2 | Early | High risk | High risk | Indeterminate | 12 | Usual care | Tight control^{b} |
Smolen [60] | Certain | 2014 | RCT | 2 | Est’lishd | Low risk | Low risk | Low risk | 12 | DMARD | Certolizumab/DMARD |
Smolen [61] | Go After | 2009 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 6 | DMARD | Golimumab/DMARD |
Smolen [62] | Option | 2008 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 6 | MTX | Tocilizumab/MTX |
Smolen [63] | Rapid2 | 2008 | RCT | 4 | Est’lishd | Low risk | Low risk | Low risk | 6 | MTX | Certolizumab/MTX |
Soubrier [64] | Guepard | 2009 | RCT | 2 | Early^{a} | Low risk | High risk | Unclear | 12 | MTX | Adalimumab/MTX |
St. Clair [65] | – | 2004 | RCT | 3 | Early | Low risk | Low risk | Low risk | 12 | MTX | Infliximab/MTX |
Symmons [66] | Brosg | 2006 | RCT | 2 | Est’lishd | High risk | Low risk | Low risk | 36 | Symptomic | Combination DMARDs |
Tak [67] | Image | 2010 | RCT | 3 | Early | Low risk | Low risk | Low risk | 12 | MTX | Rituximab/MTX |
Takeuchi [68] | Hopeful-1 | 2014 | RCT | 2 | Early | Low risk | Low risk | Low risk | 6 | MTX | Adalimumab/MTX |
Taylor [69] | RA Beam | 2017 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 6 | MTX |
Baracitinib/MTX or Adalimumab/MTX |
van der Heijde [70] | Oral Scan | 2013 | RCT | 3 | Est’lishd | Low risk | Low risk | Low risk | 6 | MTX | MTX/Tofacitinib |
Van Ejik [71] | Stream | 2012 | RCT | 2 | Early | Uncertain | Low risk | Low risk | 24 | Usual care | Intensive treatment |
van Vollenhoven [72] | Oral Standard | 2012 | RCT | 4 | Est’lishd | Low risk | Low risk | Low risk | 6 | MTX | Tofacitinib/MTX or Adalimumab/MTX |
Verstappen [73] | Camera | 2007 | Open label | 2 | Early | High risk | High risk | Indeterminate | 24 | Usual care | Combination DMARDs |
Weinblatt [74] | Go Further | 2013 | RCT | 2 | Est’lishd | Low risk | Low risk | Low risk | 6 | MTX | Golimumab/MTX |
Westhovens [75] | – | 2009 | RCT | 2 | Early | Low risk | Low risk | Low risk | 12 | MTX | Abatacept/MTX |